Cencora, Inc.
Cencora, Inc. (COR) Stock Competitors & Peer Comparison
See (COR) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| COR | $311.99 | +0.59% | 60.7B | 37.52 | $8.32 | +0.73% |
| MCK | $835.00 | +0.81% | 102.2B | 24.11 | $34.61 | +0.38% |
| CAH | $205.61 | +1.62% | 48.4B | 29.59 | $6.95 | +0.99% |
| ABC | $179.98 | -0.23% | 36.1B | 21.92 | $8.21 | N/A |
| HSIC | $76.12 | -1.40% | 8.7B | 23.28 | $3.27 | N/A |
| PBH | $58.75 | +0.77% | 2.8B | 15.18 | $3.87 | N/A |
| PDCO | $31.33 | +0.00% | 2.8B | 20.48 | $1.53 | +1.66% |
| GRDN | $37.59 | -0.90% | 2.4B | 48.19 | $0.78 | N/A |
| ACH | $3.83 | +11.99% | 292.8M | -2.86 | -$1.34 | N/A |
| OMI | $2.68 | +8.94% | 207.1M | -0.47 | -$5.69 | N/A |
Stock Comparison
COR vs MCK Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, MCK has a market cap of 102.2B. Regarding current trading prices, COR is priced at $311.99, while MCK trades at $835.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas MCK's P/E ratio is 24.11. In terms of profitability, COR's ROE is +1.01%, compared to MCK's ROE of -2.45%. Regarding short-term risk, COR is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check MCK's competition here
COR vs CAH Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, CAH has a market cap of 48.4B. Regarding current trading prices, COR is priced at $311.99, while CAH trades at $205.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas CAH's P/E ratio is 29.59. In terms of profitability, COR's ROE is +1.01%, compared to CAH's ROE of -0.59%. Regarding short-term risk, COR is less volatile compared to CAH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check CAH's competition here
COR vs ABC Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, ABC has a market cap of 36.1B. Regarding current trading prices, COR is priced at $311.99, while ABC trades at $179.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas ABC's P/E ratio is 21.92. In terms of profitability, COR's ROE is +1.01%, compared to ABC's ROE of +1.01%. Regarding short-term risk, COR is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ABC's competition here
COR vs HSIC Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, HSIC has a market cap of 8.7B. Regarding current trading prices, COR is priced at $311.99, while HSIC trades at $76.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas HSIC's P/E ratio is 23.28. In terms of profitability, COR's ROE is +1.01%, compared to HSIC's ROE of +0.12%. Regarding short-term risk, COR is less volatile compared to HSIC. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check HSIC's competition here
COR vs PBH Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, PBH has a market cap of 2.8B. Regarding current trading prices, COR is priced at $311.99, while PBH trades at $58.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas PBH's P/E ratio is 15.18. In terms of profitability, COR's ROE is +1.01%, compared to PBH's ROE of +0.10%. Regarding short-term risk, COR is less volatile compared to PBH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check PBH's competition here
COR vs PDCO Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, PDCO has a market cap of 2.8B. Regarding current trading prices, COR is priced at $311.99, while PDCO trades at $31.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas PDCO's P/E ratio is 20.48. In terms of profitability, COR's ROE is +1.01%, compared to PDCO's ROE of +0.06%. Regarding short-term risk, COR is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check PDCO's competition here
COR vs GRDN Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, GRDN has a market cap of 2.4B. Regarding current trading prices, COR is priced at $311.99, while GRDN trades at $37.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas GRDN's P/E ratio is 48.19. In terms of profitability, COR's ROE is +1.01%, compared to GRDN's ROE of +0.28%. Regarding short-term risk, COR is less volatile compared to GRDN. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check GRDN's competition here
COR vs ACH Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, ACH has a market cap of 292.8M. Regarding current trading prices, COR is priced at $311.99, while ACH trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas ACH's P/E ratio is -2.86. In terms of profitability, COR's ROE is +1.01%, compared to ACH's ROE of +7.33%. Regarding short-term risk, COR is less volatile compared to ACH. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check ACH's competition here
COR vs OMI Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, OMI has a market cap of 207.1M. Regarding current trading prices, COR is priced at $311.99, while OMI trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas OMI's P/E ratio is -0.47. In terms of profitability, COR's ROE is +1.01%, compared to OMI's ROE of +7.33%. Regarding short-term risk, COR is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check OMI's competition here
COR vs GEG Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, GEG has a market cap of 56.9M. Regarding current trading prices, COR is priced at $311.99, while GEG trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas GEG's P/E ratio is -4.20. In terms of profitability, COR's ROE is +1.01%, compared to GEG's ROE of -0.21%. Regarding short-term risk, COR is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check GEG's competition here
COR vs HX Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, HX has a market cap of 53.4M. Regarding current trading prices, COR is priced at $311.99, while HX trades at $2.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas HX's P/E ratio is -1.84. In terms of profitability, COR's ROE is +1.01%, compared to HX's ROE of -1.07%. Regarding short-term risk, COR is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check HX's competition here
COR vs WGRX Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, WGRX has a market cap of 8.2M. Regarding current trading prices, COR is priced at $311.99, while WGRX trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas WGRX's P/E ratio is -0.08. In terms of profitability, COR's ROE is +1.01%, compared to WGRX's ROE of +1417.60%. Regarding short-term risk, COR is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check WGRX's competition here
COR vs ZYXI Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, ZYXI has a market cap of 3.8M. Regarding current trading prices, COR is priced at $311.99, while ZYXI trades at $0.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas ZYXI's P/E ratio is -0.05. In terms of profitability, COR's ROE is +1.01%, compared to ZYXI's ROE of -18.07%. Regarding short-term risk, COR is more volatile compared to ZYXI. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check ZYXI's competition here
COR vs SNYR Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, SNYR has a market cap of 3.7M. Regarding current trading prices, COR is priced at $311.99, while SNYR trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas SNYR's P/E ratio is -0.30. In terms of profitability, COR's ROE is +1.01%, compared to SNYR's ROE of +0.83%. Regarding short-term risk, COR is less volatile compared to SNYR. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check SNYR's competition here
COR vs MEHA Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, MEHA has a market cap of 695.5K. Regarding current trading prices, COR is priced at $311.99, while MEHA trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas MEHA's P/E ratio is 10.10. In terms of profitability, COR's ROE is +1.01%, compared to MEHA's ROE of +1.19%. Regarding short-term risk, COR is less volatile compared to MEHA. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check MEHA's competition here
COR vs RDGT Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, RDGT has a market cap of 426. Regarding current trading prices, COR is priced at $311.99, while RDGT trades at $1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas RDGT's P/E ratio is -0.03. In terms of profitability, COR's ROE is +1.01%, compared to RDGT's ROE of +0.42%. Regarding short-term risk, COR is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for COR.Check RDGT's competition here
COR vs CVET Comparison April 2026
COR plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, COR stands at 60.7B. In comparison, CVET has a market cap of 0. Regarding current trading prices, COR is priced at $311.99, while CVET trades at $20.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
COR currently has a P/E ratio of 37.52, whereas CVET's P/E ratio is -69.97. In terms of profitability, COR's ROE is +1.01%, compared to CVET's ROE of -0.06%. Regarding short-term risk, COR is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for COR.Check CVET's competition here